Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium-dependent osteogenic signaling is a complex biological process that utilizes calcium ions as second messengers to regulate the differentiation of mesenchymal stem cells into bone-forming osteoblasts and the subsequent mineralization of the bone matrix (nih.gov, mdpi.com). This signaling network is primarily initiated by the sensing of extracellular calcium levels through the calcium-sensing receptor (CaSR), a G-protein-coupled receptor that triggers intracellular calcium release and downstream kinase cascades (nih.gov). Additionally, calcium influx through L-type voltage-gated calcium channels (L-VGCCs) and store-operated calcium entry (SOCE) channels, such as Orai1, is essential for maintaining the calcium oscillations required to activate the calcineurin-NFAT pathway (nih.gov). Once activated, calcineurin dephosphorylates NFAT transcription factors, facilitating their nuclear translocation to upregulate the expression of master osteogenic regulators like RUNX2 and BMP-2 (nih.gov). The pathway also involves the activation of calmodulin-dependent protein kinases (CaMKs) and the MAPK/ERK signaling cascade, which further support osteoblast proliferation and survival (nih.gov). Drugs such as strontium ranelate act as agonists of this signaling pathway to treat osteoporosis by promoting bone formation and inhibiting resorption (nih.gov). Conversely, inhibitors of pathway components, such as the calcineurin inhibitors cyclosporine and tacrolimus, are known to cause significant bone loss and increased fracture risk as a side effect (nih.gov). Understanding this pathway is crucial for developing novel anabolic therapies that can restore bone density in metabolic bone disorders like osteoporosis and osteomalacia (nih.gov). Therapeutic challenges include managing systemic calcium homeostasis and avoiding off-target effects in other calcium-sensitive tissues like the heart and kidneys (nih.gov).
Agonism of the calcium-sensing receptor (CaSR), activation of L-type voltage-gated calcium channels, inhibition of calcineurin, and modulation of store-operated calcium entry (SOCE).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium-dependent osteogenic signaling.